Navigation Links
Nventa Appoints Gordon H. Busenbark to Board of Directors
Date:5/28/2008

- Busenbark Provides Additional Global Corporate Finance, Management and

Manufacturing Experience -

SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today the appointment of Gordon H. Busenbark to the company's board of directors. Mr. Busenbark currently serves as the chief financial officer of Xytis Pharmaceuticals, a privately held development-stage specialty pharmaceuticals company focused on diseases of the central nervous system.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"With his extensive experience in the pharmaceutical, biotech and vaccine industries, Gordon is a valuable addition to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His 28 years of industry experience include overseeing billion dollar businesses in both the U.S. and Europe. We believe this key global experience, coupled with his proven track record in corporate finance and manufacturing, will serve Nventa well as we continue to advance our lead product candidate through development and toward commercialization."

Prior to joining Xytis in 2007, Mr. Busenbark was the chief financial officer of Encysive Pharmaceuticals, a publicly traded specialty pharmaceuticals company focused on vascular disease. In this role, he was responsible for securing external financing, all aspects of Security and Exchange Commission (SEC) reporting, Sarbanes-Oxley compliance, budgeting, forecasting, strategic planning and investor relations activities. From 1981 through 2004, Mr. Busenbark held various leadership positions with Baxter Healthcare Corporation, including president of Baxter BioScience's plasma therapeutics business in Vienna, Austria. Mr. Busenbark began his career as a senior financial analyst at Burroughs Corporation. He received a bachelo
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
10. Codexis Appoints Singapore Laboratories Managing Director
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2
... PAT and QbD remains a field that still lacks ... Pharma IQ across the PAT and QbD community it was  found ... not implementing PAT/QbD was due to a lack of personnel with ... opens its doors to industry specialists from the PAT and QbD ...
... Germany, October 11, 2011 joimax® opened ... patronage of the German Academy for Neurosurgery (GANS) and ... Neurosurgery at the "Städtisches Klinikum" in Karlsruhe, Prof. Dr. ... place in Karlsruhe, South Germany, October 5 to 8. ...
... Oct. 11, 2011 STAAR Surgical Company (NASDAQ: STAA ) ... quarter ended September 30, 2011 on Monday, October 24, 2011 ... will host a conference call on Monday, October 24, 2011 ... to discuss the Company,s third quarter results and recent corporate ...
Cached Biology Technology:Establishing the Correct QbD Strategies and Tools Early in the Development Process is Key to Ensuring we Have Robust Quality Products Downstream 2joimax® Inspires Thai-German Neurosurgery Congress Participants for TESSYS® 2joimax® Inspires Thai-German Neurosurgery Congress Participants for TESSYS® 3STAAR Surgical Announces Third Quarter 2011 Results Release Date and Conference Call 2
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Dec. 17, 2012 The University of Houston (UH) ... thanks to a computer hardware donation from Total, a ... nodes that will occupy four racks of space. ... computing resources," said Jaspal Subhlok, chairman of UH,s department ...
... December 2012)New research released today, on the eve of an ... agencies and investors for a growing spate of violent clashes ... of resources from the rural poor to investors is underway, ... Top global experts at the meeting noted as well that ...
... up on snack foods may increase cancer risk in ... cancers. Published early online in CANCER , a ... suggests that an eating pattern low in snack foods ... syndromelower their risk. Lynch syndrome is an inherited ...
Cached Biology News:Total donates high-speed computer cluster to UH 2New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 2New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 3New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 4Snack attack: Eating unhealthy snack foods may affect cancer risk in patients with Lynch syndrome 2
...
...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The version upgrade allows upgrade of an established version of...
Biology Products: